SEC Form 4 · accession 0001144204-17-018955
ANI PHARMACEUTICALS INC · ANIP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James G. Marken
Officer — SVP Ops & Prod Dev
Period of report
Mar 31, 2017
Accepted (ET)
Apr 4, 2017 · 6:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001023024
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 31, 2017 | A | 3,625 | $0.00 | A | 51,827 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $49.51 | Mar 31, 2017 | A | 7,250 | A | Mar 31, 2017 | Mar 30, 2027 | Common Stock | 7,250 | 7,250 | D |
Explanation of responses
- F1The restricted stock and the stock options vests in equal annual installments on the first, second, third and fourth anniversaries of the grant date.